IRIX Quote, Financials, Valuation and Earnings

Electromed has a net margin of -16.69% compared to IRIDEX's net margin of 12.11%. IRIDEX's return on equity of -157.91% beat Electromed's return on equity of 15.91%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 73.91%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 68.26%. Given that IRIDEX has higher upside potential than Electromed, analysts believe IRIDEX is more attractive than Electromed.

IRIDEX has a beta of 0.692, which suggesting that the stock is 30.819% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are smaller than Electromed quarterly revenues of $16.3M. IRIDEX's net income of -$1.9M is lower than Electromed's net income of $2M. Notably, IRIDEX's price-to-earnings ratio is -- while Electromed's PE ratio is 29.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.39x versus 3.30x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical has a net margin of -16.69% compared to IRIDEX's net margin of --. IRIDEX's return on equity of -157.91% beat Modular Medical's return on equity of --.

IRIDEX has a consensus price target of --, signalling upside risk potential of 73.91%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 676.7%. Given that Modular Medical has higher upside potential than IRIDEX, analysts believe Modular Medical is more attractive than IRIDEX.

IRIDEX has a beta of 0.692, which suggesting that the stock is 30.819% less volatile than S&P 500. In comparison Modular Medical has a beta of -4.845, suggesting its less volatile than the S&P 500 by 584.542%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are larger than Modular Medical quarterly revenues of --. IRIDEX's net income of -$1.9M is higher than Modular Medical's net income of -$4.8M. Notably, IRIDEX's price-to-earnings ratio is -- while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.39x versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -16.69% compared to IRIDEX's net margin of -2.16%. IRIDEX's return on equity of -157.91% beat Myomo's return on equity of -48.64%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 73.91%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 91.12%. Given that Myomo has higher upside potential than IRIDEX, analysts believe Myomo is more attractive than IRIDEX.

IRIDEX has a beta of 0.692, which suggesting that the stock is 30.819% less volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are smaller than Myomo quarterly revenues of $12.1M. IRIDEX's net income of -$1.9M is lower than Myomo's net income of -$260.1K. Notably, IRIDEX's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.39x versus 5.61x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -16.69% compared to IRIDEX's net margin of -118.53%. IRIDEX's return on equity of -157.91% beat Stereotaxis's return on equity of -139.2%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 73.91%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 115.31%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

IRIDEX has a beta of 0.692, which suggesting that the stock is 30.819% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are larger than Stereotaxis quarterly revenues of $6.3M. IRIDEX's net income of -$1.9M is higher than Stereotaxis's net income of -$7.5M. Notably, IRIDEX's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.39x versus 6.61x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.